Technical Analysis for FOLD - Amicus Therapeutics, Inc.

Grade Last Price % Change Price Change
F 11.58 0.87% 0.10
FOLD closed up 0.87 percent on Monday, March 18, 2024, on 77 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
3 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Bullish Engulfing Bullish 0.00%
Stochastic Buy Signal Bullish 0.00%
Oversold Stochastic Weakness 0.00%
Doji - Bullish? Reversal 0.87%
Lower Bollinger Band Walk Weakness 0.87%
Oversold Stochastic Weakness 0.87%
Lower Bollinger Band Walk Weakness 0.35%
Lower Bollinger Band Touch Weakness 0.35%
Oversold Stochastic Weakness 0.35%
Pocket Pivot Bullish Swing Setup -1.95%

   Recent Intraday Alerts

Alert Time
Up 3% about 19 hours ago
60 Minute Opening Range Breakout about 19 hours ago
Rose Above Previous Day's High about 22 hours ago
Up 2% about 22 hours ago
Up 1% about 22 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Amicus Therapeutics, Inc. Description

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company's development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company's primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Rare Diseases Enzymes Orphan Drug Lipid Storage Disorders Orphan Disease Inborn Errors Of Metabolism Enzyme Replacement Therapy Fabry Disease Lysosomal Storage Disorder Gaucher Disease Lysosomal Storage Disorders Pompe Disease Rare And Orphan Diseases

Is FOLD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 14.57
52 Week Low 9.7
Average Volume 3,044,491
200-Day Moving Average 12.39
50-Day Moving Average 12.90
20-Day Moving Average 12.76
10-Day Moving Average 12.09
Average True Range 0.49
RSI (14) 34.21
ADX 24.59
+DI 13.13
-DI 29.72
Chandelier Exit (Long, 3 ATRs) 12.55
Chandelier Exit (Short, 3 ATRs) 12.85
Upper Bollinger Bands 14.38
Lower Bollinger Band 11.14
Percent B (%b) 0.14
BandWidth 25.40
MACD Line -0.42
MACD Signal Line -0.24
MACD Histogram -0.1798
Fundamentals Value
Market Cap 3.4 Billion
Num Shares 293 Million
EPS -0.59
Price-to-Earnings (P/E) Ratio -19.63
Price-to-Sales 10.67
Price-to-Book 29.84
PEG Ratio -0.18
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.27
Resistance 3 (R3) 12.28 12.06 12.16
Resistance 2 (R2) 12.06 11.88 12.06 12.12
Resistance 1 (R1) 11.82 11.78 11.94 11.81 12.08
Pivot Point 11.60 11.60 11.66 11.60 11.60
Support 1 (S1) 11.36 11.42 11.48 11.35 11.08
Support 2 (S2) 11.14 11.32 11.14 11.04
Support 3 (S3) 10.90 11.14 11.01
Support 4 (S4) 10.89